Investigational Drug Information for Myrcludex B
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Myrcludex B?
Myrcludex B is an investigational drug.
There have been 7 clinical trials for Myrcludex B.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 17th 2019.
The most common disease conditions in clinical trials are Hepatitis A, Hepatitis, and Hepatitis D. The leading clinical trial sponsors are Hepatera Ltd., Gilead Sciences, and MYR GmbH.
There are two US patents protecting this investigational drug and twenty-seven international patents.
Summary for Myrcludex B
| US Patents | 2 |
| International Patents | 27 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-04-17) |
| Vendors | 0 |
Recent Clinical Trials for Myrcludex B
| Title | Sponsor | Phase |
|---|---|---|
| A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function | Gilead Sciences | Phase 1 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Hepatera Ltd. | Phase 2 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Myrcludex B
Top disease conditions for Myrcludex B
Top clinical trial sponsors for Myrcludex B
US Patents for Myrcludex B
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Myrcludex B | See Plans and Pricing | Non-invasive method for assessing liver fibrosis progression | CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS (Angers, FR) UNIVERSITE D'ANGERS (Angers, FR) | See Plans and Pricing |
| Myrcludex B | See Plans and Pricing | Oligonucleotide chelate complex--polypeptide compositions and methods | REPLICOR INC. (Montreal, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Myrcludex B
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Myrcludex B | Australia | AU2013262416 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | Brazil | BR112014028654 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | Canada | CA2873529 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | Chile | CL2014003134 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | China | CN104349793 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | Colombia | CO7131387 | 2032-05-18 | See Plans and Pricing |
| Myrcludex B | Costa Rica | CR20140527 | 2032-05-18 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
